• Policy
• Otezla generics enter negotiations for reimb
• by Lee, Tak-Sun Dec 13, 2024 05:52am

• Company
• New PAH drug Winrevair to land in KOR next year
• by Eo, Yun-Ho Dec 13, 2024 05:52am

• Opinion
• [Reporter's view] What corporates expect from entering pharm
• by Dec 13, 2024 05:52am

• InterView
• ‘New start at a law firm…will become a trusted expert’
• by Kim, Jin-Gu Dec 13, 2024 05:52am

• Company
• "Confirmed long-term Tx effects of Camzyos…new oHCM Tx"
• by Son, Hyung Min Dec 13, 2024 05:51am

• Policy
• Martial law impacts the launch of the Pharma-Bio Committee
• by Lee, Jeong-Hwan Dec 13, 2024 05:51am

• Company
• NeuroBiogen enters into Binding Term Sheet with US Company
• by Lee, Seok-Jun Dec 12, 2024 05:50am

• Company
• 'Effective in Asian patients' Leclaza vs Tagrisso comb
• by Son, Hyung Min Dec 12, 2024 05:49am

• Policy
• HIRA sets plan for performance assessment of 'Qarziba'
• by Lee, Tak-Sun Dec 12, 2024 05:49am

• Company
• Merck Biopharma Korea and LG Chem will comarket Glucophage
• by Whang, byung-woo Dec 12, 2024 05:49am